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complications that are related to transvenous pacing
systems.
Persistent left superior vena cava (literature) 0.3e0.5%
Persistent left superior vena cava (current study) 0.17%Since their introduction in the 1960s, pacemakers, the only
effective treatment for symptomatic bradycardia, have
reduced symptoms and the recurrence of syncope and have
improved survival in high-risk populations.
Conventional pacing systems consist of a pacemaker that
contains electronics and a battery and is typically implan-
ted in a subcutaneous pocket in the chest. One or more
leads thread from the device pocket through the veins and
into the heart to conduct the pacing therapy to the desired
site. When veins cannot be used, the surgical procedure
includes implanting epicardial leads that link the device to
the heart.
Steckiewicz et al. aimed to determine the prevalence
and variations of persistent left superior vena cava (PLSVC)
and to conduct outpatient follow-ups regarding the func-
tioning of the device and the clinical condition of the re-
cipients using data from device placement procedures that
were conducted over a 12-year period.1 Although
the prevalence of PLSVC in the population has been
reported to be approximately 0.3e0.5%, the prevalence
of this systemic vein anomaly was 0.17% in the evaluated
patient population (Table 1).1 This anomaly is usually found
incidentally during post-mortem examinations, invasive
cardiological procedures, cardio-thoracosurgical pro-
cedures or echocardiography.
The presence of PLSVC and its morphology (confluence
angles, valves) hinder manipulation of pacemaker leads and
placement of leads in the right ventricle, as this situationof Hellenic Cardiological
.04.003
cal Society. Publishing services by
licenses/by-nc-nd/4.0/).requires negotiating the acute angle between the orifice of
the coronary sinus and the tricuspid valve. Most impor-
tantly, the outpatient follow-ups in the seven patients
diagnosed with PLSVC, as well as the assessments con-
ducted at these follow-ups, confirmed normal pacing pa-
rameters and lead placements.
Based on the above data, the assumption was made that
there were no cases where epicardial leads had to be used
to ensure cardiac pacing. There was also no report on the
incidence of peri- or post-procedural complications in the
evaluated population, irrespective of venous anomalies. It
is possible that complications have been greatly reduced in
recent years because of technological advances. However,
serious adverse events can still occur and have been re-
ported at a rate of 20% 5 years after the procedure, with
the most common complications involving the pacing lead
(11%) and pocket (8%) (Table 1).2e4 The most common
complications also include pneumo- or hemothorax after
subclavian vein puncture, pocket hematoma, erosion or
infection, vein stenosis or occlusion, endocarditis, tricuspid
valve trauma, connection troubles, and lead fractures,
along with other less common malfunctions.
It is the post-procedural complications, rather than the
venous anomalies, that have urged advances toward the
present and future transcatheter pacing systems, such as
miniaturized pacemaker systems that can be delivered via
catheter through the femoral vein and implanted directly
into the heart. This new technology eliminates the need for
a device pocket and the need to insert a pacing lead,
thereby eliminating two main sources of complicationsPacing lead related complications at 5 years 11%
Pocket related complications at 5 years 8%
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108 Editorialassociated with traditional pacing systems while still
providing similar benefits.
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